Samsung Medical Center
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma
Phase 3
Completed
- Conditions
- Gastric CancerSurgery
- Interventions
- Drug: Capecitabine, cisplatin, Radiotherapy (+/-)
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2011-11-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 458
- Registration Number
- NCT00323830
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC
Phase 2
Completed
- Conditions
- Colorectal CancerMetastasis
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00313859
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
Phase 3
Completed
- Conditions
- Gastric CancerMetastases
- Interventions
- Drug: FOLFIRIDrug: DP
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-01-12
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT00313872
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of